Rhythm Pharmaceuticals
Presença
Rhythm Pharmaceuticals é uma das ...
Rhythm Pharmaceuticals é uma empresa listada sob o símbolo RYTM (US).
Executivos
Veja o organograma con seus 18 executivos principais
Biografias mais buscadas da Rhythm Pharmaceuticals
- David Meeker, Chairman of Board, President and Chief Executive Off...
- Ed Mathers, Lead Independent Director
- Stuart Arbuckle, Director
Criar um alerta
para seguir os movimentos de executivos da Rhythm Pharmaceuticals.
Farmacêutica
Rhythm Pharmaceuticals possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals to Present at Investor Conferences in September | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers | Rhythm Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Rhythm Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Stuart Arbuckle 
Ligue para a Rhythm Pharmaceuticals em +1 857...
